This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
March 4, 2014 /PRNewswire/ --
Ocriplasmin Research to Better Inform Treatment (ORBIT) study designed to generate further data on the"real world"use of JETREA®
ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines for the back of the eye, today announces that it is to shortly initiate a US Phase IV study with JETREA
®. The Ocriplasmin Research to Better Inform Treatment (ORBIT) study is designed to generate further data on the real-world use of JETREA
The ORBIT study will recruit 1,500 patients with symptomatic vitreomacular adhesion (VMA)/vitreomacular traction (VMT) patients across 120 retina centers in the US. The prospective, observational study will assess clinical outcomes and safety of JETREA
® administered in a real-world setting for the treatment of symptomatic VMA/VMT by assessing both anatomical and functional outcomes. The study will look at a number of parameters including resolution of VMA, Full Thickness Macular Hole (FTMH) closure, changes in visual acuity (VA) and occurrence and time to vitrectomy. It will also monitor adverse drug reactions (ADRs) and changes from baseline in ocular signs and symptoms across time. These data will further characterize the efficacy and safety profile of the product and provide data complementary to those from the phase III clinical program and its first year on the market.
Patients will be followed for up to 12 months following treatment with JETREA
®. The ORBIT study is expected to start recruiting patients this month and is due to complete in mid-2016.
Patrik De Haes, CEO of ThromboGenics, comments
:"The start of the ORBIT study in theUSreflects ThromboGenics'commitment to gain further knowledge on the real world use of JETREA®. We feel that it is important with such a novel treatment option as JETREA®to conduct a significant post marketing study in order to assess which patients gain the greatest benefit from the first pharmacological option that is designed for the treatment of symptomatic VMA/VMT. The desire for more information on the real-world experience with JETREA®is shared by our partner Novartis/Alcon which is conducting a parallel patient study outside the US."AboutJETREA®(ocriplasmin)
® (ocriplasmin) is a truncated form of human plasmin. JETREA
® is a selective proteolytic enzyme that cleaves fibronectin, laminin and collagen, three major components of the vitreoretinal interface that play an important role in vitreomacular adhesion.
In the US and
® is indicated for the treatment of symptomatic vitreomacular adhesion (VMA). In
® is indicated for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter ≤ 400 microns.
® has been evaluated in two multi-center, randomized, double-masked Phase III trials conducted in the US and
Europe involving 652 patients with vitreomacular adhesion. Both studies met the primary endpoint of resolution of VMA at day 28.
JETREA's Phase III program found that 26.5% of patients treated with ocriplasmin saw resolution of VMA, compared with 10.1% of patients receiving placebo (p<0.01). The Phase III program also showed that JETREA was generally well tolerated with most adverse events being transient and mild in severity.